Division of Gynecologic Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania.
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):28-33. doi: 10.1097/GCO.0000000000000918. Epub 2023 Oct 11.
To summarize the recent updates in cervical cancer from prevention and early detection to the management of early stage and recurrent disease as well as future areas of exploration.
The importance of the human papilloma virus vaccine and screening continue to make an impact in reducing the global burden of cervical cancer. In early-stage, low risk disease, new studies have demonstrated the role of less radical surgery with similar disease related outcomes. Efforts to improve outcomes in locally advanced cervical cancer have been reported. The incorporation of adjuvant chemotherapy, novel agents and checkpoint inhibitors, with the latter impacting disease free survival. In advanced/recurrent disease, the role of immunotherapy continues to make an impact and, in addition to recurrent disease, has now moved to the frontline for patients with programmed cell death ligand 1 expression. Tisotumab vedotin, an antibody drug conjugate, and other novel agents continue to be studied in this setting.
In this review, we discuss prevention measures and the outcomes of recent trials in all stages of cervical cancer. As therapies continue to evolve, ongoing trials and new areas of exploration will continue to identify opportunities to improve survival in cervical cancer.
总结宫颈癌从预防和早期检测到早期和复发性疾病的管理以及未来探索领域的最新进展。
人乳头瘤病毒疫苗和筛查的重要性继续在降低宫颈癌的全球负担方面产生影响。在早期、低危疾病中，新的研究表明，手术的激进程度降低，而疾病相关结局相似。为了提高局部晚期宫颈癌的治疗效果，已经有报道。辅助化疗、新型药物和检查点抑制剂的应用，后者影响无疾病生存。在晚期/复发性疾病中，免疫疗法继续产生影响，除了复发性疾病，现在对程序性死亡配体 1 表达的患者也用于一线治疗。抗体药物偶联物 tisotumab vedotin 以及其他新型药物在这一领域仍在研究中。
在这篇综述中，我们讨论了宫颈癌各阶段的预防措施和最近试验的结果。随着治疗方法的不断发展，正在进行的试验和新的探索领域将继续确定改善宫颈癌患者生存的机会。
